ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[PRL, HHEX, CCR2, HGS, PLK2, TEK]
GO:0042417;dopamine metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.503361109538115;117.20956159213898;6.409777797693995;0.003922898544731914;0.6787156999164222;[NR4A2, DRD4]
GO:0014068;positive regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;5.602686357784832;0.007979625599047746;0.6615216408886768;[PDGFC, F2R, PTK2, GH1, CD28, TEK]
GO:1903361;protein localization to basolateral plasma membrane;6.0;1.0;0.8231203125901445;9.628524252492122;65.42666064804821;7.8311634786251565;0.002189771451718415;0.7236063770733796;[CAV1, LIN7A]
GO:1904211;membrane protein proteolysis involved in retrograde protein transport, ER to cytosol;7.0;1.0;0.8509193652572005;9.628524252492122;102.595646606244;9.083926447120524;0.003433783961823618;0.8154717862087246;[HM13]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[, NUP107, TFRC, AKT1, LYN, ABCA1, MMP12, CSE1L, AP2M1, ACAP1, SLC27A2, LIN7A, ITGB6, LRP1, ACTN4, MSR1, EGR2, POLA2, CD24, CD3G, CD36, STX11, RAMP1, SCARB2, NUP155, NASP, NUP62, NUP133, TBC1D9, CHI3L1, NUP54, NUP35, RAN, NUP85, NUP88, DENND1B, LAMP2, RAB32, CALCRL, BCL6, CCDC22, NLGN1, UNC93B1, NLRC4, STXBP2, TRAM2, XPO1, TMED6, TLR4, TLR2, RANBP1, LILRB1, NUPL2, TSC2, ATP1B1, HGS, SUCNR1, NLRP3, TGFB1, DNM2]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[TGFB1, CAV1, CLDN4, TLR2]
GO:0060009;Sertoli cell development;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;53.96940310801817;7.138016298065211;0.0018063073527159576;0.6552794972956795;[ARID4A, FLNA, SDC1]
GO:0008344;adult locomotory behavior;3.0;0.8436909121759173;0.6199657686781032;9.158520623246385;24.575257889458463;5.459585514144159;8.225117652639858E-4;0.47732376968016754;[ABHD12, CHL1, DRD4, SCN1A, NR4A2]
GO:0003056;regulation of vascular smooth muscle contraction;8.0;0.8259837884571596;0.7879918942285797;9.533214072687796;76.73452313494074;7.697632086000634;0.0025682354327391786;0.7686572628545723;[DOCK5, CHRM1, P2RX1]
GO:0042532;negative regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1231.6194323740242;7.379178354882098;0.041221194016031935;0.8098004765652196;[PPP2R1A, CAV1]
GO:0003057;regulation of the force of heart contraction by chemical signal;8.0;0.7436939687323844;0.7468469843661922;8.992535485772125;28.25379719464655;7.9853141584524145;9.456291653381902E-4;0.7833693374183408;[CAV1]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, GHSR, ANXA3, GAB1, ADAM12, CHI3L1, ENG, C5AR1, PTGS2, CXCR2, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0000188;inactivation of MAPK activity;13.0;0.8436909121759173;0.8844004208555951;9.558319993818873;2610.871803759405;6.518977089658987;0.08738352963975493;0.7959357562962344;[DUSP2, DUSP1, CAV1, DUSP6, PPP2R1A]
GO:0050796;regulation of insulin secretion;9.0;0.8259837884571596;0.8092325194088689;9.533214072687796;205.48125160941495;4.61801832846594;0.006877272570246766;0.6324062972578516;[KCNG2, GHSR, BLK, CNR1]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, PROK2, MAP4K1, MAP2K2, DUSP6, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, DRD4, PKN1]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, EGR1, TGFB1, CAV1, NR4A2, NOX4, CD24, AGTRAP, TLR2, CXCR4, PTGS2, TEK]
GO:0051001;negative regulation of nitric-oxide synthase activity;7.0;1.0;0.8509193652572005;9.628524252492122;123.18001952109483;7.8311634786251565;0.0041227243985507795;0.7514054297404357;[CNR1, CAV1]
GO:0071375;cellular response to peptide hormone stimulus;7.0;0.7369933605727446;0.7194160455435727;9.117698628726131;386.0268190343683;4.727217620430932;0.012919970231498398;0.5926694942041391;[CYFIP1, AKT1, GHSR, LHCGR, ARG1, GLP2R, POR, CEACAM1, ADCY9, FOXO1, PRKAR2B, TGFB1, CAV1, CDC6, TSHR, NR4A2, NR4A1]
GO:0072584;caveolin-mediated endocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;8.16763571524637;9.517765291732001E-4;0.7408135829017477;[CAV1]
GO:0033137;negative regulation of peptidyl-serine phosphorylation;10.0;0.8933024483968273;0.861892236059334;9.56398573135455;780.3281191277907;6.518977089658987;0.026116879897493853;0.7486218033895181;[CAV1]
GO:2000352;negative regulation of endothelial cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.9263443150347;6.444869117505266;0.0043485178181058145;0.7258315315665724;[TEK]
GO:0030301;cholesterol transport;7.0;0.7763722522362496;0.7391054913753253;8.999915593069748;37.84975072563126;5.845247994956144;0.0012667970942227542;0.6498456195510879;[ABCA1, MSR1, CAV1, CD36]
GO:0033138;positive regulation of peptidyl-serine phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;5.152100814396198;0.026061291479152104;0.6787196871063318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TCL1A, AKT1, IFNA14, IFNA16, IFNA10, PTGS2, IFNA21, TGFB1, CAV1]
GO:0042426;choline catabolic process;8.0;1.0;0.875;9.628524252492122;257.1096326794824;7.9853141584524145;0.008605228022135562;0.7833693374183408;[SLC44A1]
GO:0070836;caveola assembly;7.0;1.0;0.8509193652572005;9.628524252492122;77.9983017477017;8.390779266560578;0.002610532965581378;0.7800242071602487;[CAV1]
GO:0071805;potassium ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.456673995565463;120.6235085317852;4.695669262696007;0.004037160276449102;0.636377369645515;[KCNK5, KCNG2, KCNE3, KCNE4, SLC1A3, KCNMB3, KCNN3, KCNH1, KCNJ15, KCNJ16, ATP1B2, ATP1B1, KCNQ1]
GO:0060355;positive regulation of cell adhesion molecule production;5.0;1.0;0.7902410118609202;9.628524252492122;40.679961272662325;8.390779266560578;0.0013615216942077584;0.7193458537639684;[COLEC12, CAV1]
GO:0098909;regulation of cardiac muscle cell action potential involved in regulation of contraction;6.0;1.0;0.8231203125901445;9.628524252492122;24.09825301254981;7.697632086000634;8.065468413103714E-4;0.7167775754447168;[CAV1]
GO:2000251;positive regulation of actin cytoskeleton reorganization;9.0;1.0;0.896240625180289;9.628524252492122;130.7363647434596;6.8867018697843045;0.004375628472874139;0.7484268790654467;[NRP1, STAP1, TEK]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[TNFAIP6, CDH5, GHSR, IL1R2, TNFRSF1B, CALCRL, NLRP3, ELANE, NLRP12, TEK, FCGR2B]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, KCNG2, TCL1A, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CAV1, CD3G, CD3E, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, NLRC4, SAMHD1, RAD51, P2RX1]
GO:0007268;chemical synaptic transmission;7.0;0.7369933605727446;0.7194160455435727;8.663443356448536;23.173347188538074;3.922001705478042;7.755910757418987E-4;0.5514907148670789;[CHRM1, GRM5, CHRNB4, NPY1R, SLC1A3, GJC1, SV2A, HRH4, KCNMB3, GABRE, DRD4, EGR3, HTR1E, PCDHB14, P2RX1, PNOC, PCDHB16, PCDHB4, GPR19]
GO:1900027;regulation of ruffle assembly;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;51.76168527241457;6.444869117505266;0.001732417023575362;0.7045909063862833;[CYFIP1, NLGN1, CAV1, RHOG, TACSTD2, EPS8L1, STAP1, PFN1]
GO:0043114;regulation of vascular permeability;5.0;0.8436909121759173;0.712086467948879;9.176539128749065;21.1969122232846;6.343086423195323;7.094415761308522E-4;0.6146267465268138;[TGFB1, AZU1, CEACAM1, CXCR2, TEK]
GO:0042542;response to hydrogen peroxide;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;79.2907140195247;5.09494240055625;0.0026537888412237636;0.5507966031644187;[HP, SLC8A1, IL18RAP, MYB, DUSP1, ARG1, ADAM9, PCNA, FOXO1, SDC1, EZH2]
GO:0042543;protein N-linked glycosylation via arginine;9.0;1.0;0.896240625180289;9.628524252492122;334.4962021705506;9.777073627680469;0.011195286859610704;0.896240625180289;[KRTCAP2]
GO:0045019;negative regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;660.5757278387367;7.292166977892469;0.022108875131204346;0.747921758369865;[CAV1]
GO:0071360;cellular response to exogenous dsRNA;7.0;1.0;0.8509193652572005;9.628524252492122;172.52541059605554;7.069023426578259;0.005774270229860956;0.7124295520356204;[COLEC12, CAV1]
GO:0051894;positive regulation of focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;280.4986055833795;6.599019797332524;0.009388035896519984;0.712474179321389;[NRP1, TEK]
GO:0048015;phosphatidylinositol-mediated signaling;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;5.649939242635378;8.845336528452411E-4;0.6398575208746181;[PTAFR, AKT1, KCNH1, GSN]
GO:0048014;Tie signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;8.67846133901236;0.0010376185600805164;0.8188169164668168;[TEK]
GO:0015718;monocarboxylic acid transport;8.0;0.5640623033008358;0.6570311516504179;7.75672207559053;50.19664702939052;4.879233827729558;0.0016800366020243219;0.6245242448576669;[AQP9, SLCO2B1, CD36, SLC16A3, ABCC3, ACSL1, CEACAM1, SLC27A2, ABCB4, DRD4, ACE, SLC16A14]
GO:0098903;regulation of membrane repolarization during action potential;8.0;0.7307253602413294;0.7403626801206646;9.223059144383958;69.05931417682642;7.697632086000634;0.0023113530961506984;0.7686572628545723;[KCNE3, CAV1, FLNA]
GO:0086091;regulation of heart rate by cardiac conduction;8.0;1.0;0.875;9.628524252492122;61.172773623059015;6.193554689224359;0.002047397681241798;0.6917386748366816;[JUP, KCNE3, KCNQ1, CAV1]
GO:0086098;angiotensin-activated signaling pathway involved in heart process;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;56.25645059859106;9.083926447120524;0.0018828527740163208;0.8154717862087246;[CAV1]
GO:0051259;protein complex oligomerization;5.0;0.7763722522362496;0.6784271379790451;9.089527751759436;40.42272244673708;3.6012063575747084;0.0013529121422039536;0.47440687246051283;[CDA, TCL1A, CLDN3, MGST1, CD79B, CD79A, JUP, CD3G, CD3E, ARG1, KCNG2, CHRNB4, OLFM4, BLM, NACC2, NLRP3, CAV1, NUP62, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, NLRC4, SAMHD1, RAD51, P2RX1, TEK]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[FGF5, GAB1, BTC, CHI3L1, HBEGF, ENG, CD19, TGFB1, TRAT1, PTK2, CD28, NOX4, TEK]
GO:0090316;positive regulation of intracellular protein transport;8.0;0.7090535922965819;0.729526796148291;9.107227328858835;289.7860898249656;4.74012102526684;0.009698879635892712;0.6174100096703167;[, CHRM1, CDH1, SFN, TGFB1, JUP, FZD5, ITGAM, LRRK2, RHOU, PTGS2]
GO:0007197;adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.5544162803384;81.68848396009673;7.8311634786251565;0.0027340400432818626;0.7967266896635242;[CHRM1, HRH4]
GO:1903543;positive regulation of exosomal secretion;9.0;1.0;0.896240625180289;9.628524252492122;273.97956964224545;7.069023426578259;0.009169849630321672;0.757750811958709;[HGS, SDC1]
GO:0007195;adenylate cyclase-inhibiting dopamine receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;58.23053162461359;7.474488534686424;0.0019489234893997154;0.7784863164434164;[FLNA, DRD4]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, AKT1, PROK2, MEF2C, CLDN7, ATF3, HHLA2, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, LRG1, CHRM1, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, BCL6, KLF5, TCL1A, EDNRB, SKP2, ICOSLG, RUNX2, BTC, TGFA, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, NRP1, NRP2, PRL, CD3E, CCR2, RHOG, PDCD1LG2, CEACAM6, GNAI2, CXCR2, LILRB2, IL6R, GHSR, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, GLP2R, MMP9, LTF, S1PR3, MEIS2, TSHR, CD4, TEK]
GO:0007597;blood coagulation, intrinsic pathway;6.0;1.0;0.8231203125901445;9.628524252492122;55.78978942234946;6.943860283624253;0.0018672340444153065;0.6782296504172152;[GP1BB]
GO:0006024;glycosaminoglycan biosynthetic process;6.0;0.7586651285174919;0.7024528768488905;9.158520623246385;237.49504005673018;5.16195311083921;0.007948745259039342;0.5871028347338303;[SDC2, NDST3, ST3GAL6, OGN, SDC1]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[PYCARD, IL6R, MSH6, MELK, MSH2, LGALS12, BTK, LY96, TNFRSF11A, SFN, TGFB1, TNFSF12, CAV1, TNFRSF10C, TNFRSF10B, INHBA, CD28, CD24, CDKN1A, BRCA2, CD3E, PAWR, TNFRSF1B, TLR4, SORT1, G0S2, MLH1]
GO:0007595;lactation;6.0;1.0;0.8231203125901445;9.628524252492122;25.956233089099676;5.9928839937622085;8.687317623989867E-4;0.6295966787287501;[ABCB4, CAV1, PRL]
GO:0042310;vasoconstriction;8.0;0.7508913569872202;0.7504456784936101;9.102431156595342;39.67967046252893;6.343086423195323;0.0013280428609958766;0.6993857346658935;[CAV1, SLC8A1, EDNRB, P2RX1]
GO:0002223;stimulatory C-type lectin receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;628.1099736002739;5.618190544320798;0.02102227555412486;0.7197434780388068;[ICAM2, MUC15, LYN, CLEC4D]
GO:0060546;negative regulation of necroptotic process;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;152.26887968422463;7.379178354882098;0.0050963023699362245;0.728290889492758;[CAV1]
GO:0006027;glycosaminoglycan catabolic process;6.0;0.7866048967936545;0.7164227609869718;9.245532000236016;234.16675596998346;5.618190544320798;0.00783735058591714;0.610434838299289;[SDC2, TGFB1, OGN, SDC1]
GO:0006814;sodium ion transport;7.0;0.811012628672052;0.7564256795932265;9.310070521373587;34.16983994150393;4.629579150867016;0.001143633791982704;0.5876762583299873;[SLC8A1, SCN1A, ATP1B2, ATP1B1, SGK1, SLC22A4, SLC24A1, SLC24A4, SLC38A11, SLC5A4, SLC38A6, SLC4A7, SLC6A6]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[FGF5, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, LAT, LRRK2, SPTAN1, MAP4K1, DUSP6, HBEGF, TEK]
GO:0001523;retinoid metabolic process;8.0;0.7671156992804218;0.7585578496402109;9.193206181234276;47.546147792504925;5.334422371190153;0.0015913267778602078;0.6478026081386739;[LRP1, SDC2, DGAT2, ALDH1A1, SDC1]
GO:0071277;cellular response to calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;5.433268205826786;0.0026274528238337297;0.6009779013089371;[NLGN1, CPNE5, KCNH1, MEF2C, TUBG1]
GO:0019065;receptor-mediated endocytosis of virus by host cell;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;100.58356338669144;8.67846133901236;0.0033664413472225267;0.7947362817240173;[CAV1]
GO:2000811;negative regulation of anoikis;8.0;1.0;0.875;9.628524252492122;103.9210822679579;6.943860283624253;0.0034781451006065307;0.7301093378270707;[CAV1, PTK2, CEACAM6]
GO:0000160;phosphorelay signal transduction system;6.0;0.8436909121759173;0.7449657686781032;9.271849308553389;26.42836680105094;7.697632086000634;8.845336528452411E-4;0.7167775754447168;[KCNH1]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, HLA-DQA1, HLA-DRB4, CDKN1A, LRRC4, FCER2, HLA-DQB1, PTAFR, PTGS2, ALOX5, CSF3R, F13A1, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, BCL6, LCN2, HLA-DRA, CIITA, ITGAM, TNFRSF1B, FCGR1B, ACSL1, IL1R1, IL1R2, CCR10, CCR1, EGR1, TNFSF12, SDC1, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR6, CD36, CCR2, IL17RB, CEACAM1, RHOU, CXCR5, CXCR4, CXCR1, CXCR2, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, CXCL1, CXCL2, MMP9, SAMHD1, CD4, LTBR]
GO:0006816;calcium ion transport;8.0;0.6696747006330769;0.7098373503165385;8.690254613899192;35.67391733828006;4.3132418226548594;0.001193973908871026;0.5955793873968269;[DENND5B, SLC8A1, CTGF, F2R, CACNA2D3, CALCRL, PSEN2, CORO1A, CCR1, CAV1, ATP2A3, TMEM37, SLC24A1, SLC24A4, RAMP1]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[CDKN1A, GHSR, DUSP1, ANXA3, ARG1, ADAM9, PCNA, ABCB4, PTAFR, PTGS2, FOXO1, IGFBP7, TGFB1, ALPL, SDC1]
GO:0070588;calcium ion transmembrane transport;9.0;0.7140352122741334;0.7532582313173557;9.078477915572849;116.6808485568922;4.562137870071484;0.003905202995253044;0.629548568016852;[DENND5B, ATP2A3, SLC8A1, F2R, CACNA2D3, TMEM37, SLC24A1, SLC24A4]
GO:0034446;substrate adhesion-dependent cell spreading;6.0;1.0;0.8231203125901445;9.628524252492122;56.23121614310476;6.088194173566533;0.0018820081995007299;0.63447084575632;[NRP1, TEK]
GO:0010595;positive regulation of endothelial cell migration;9.0;0.8259837884571596;0.8092325194088689;9.488762310116963;298.6320589889849;5.2552850506314295;0.009994946262957053;0.664996147065328;[NRP1, NRP2, AKT1, ANXA3, PTGS2, TGFB1, PLK2, TEK]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD274, HHLA2, CD3E, GRAP2, BTLA, AKT1, ICOSLG, LYN, CAV1, PDCD1LG2, CD28, CD24]
GO:1903553;positive regulation of extracellular exosome assembly;8.0;1.0;0.875;9.628524252492122;166.66584496590895;8.390779266560578;0.005578155841486647;0.8041048419030481;[SDC1]
GO:0044860;protein localization to plasma membrane raft;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;66.52527293671452;8.390779266560578;0.002226541016333207;0.7800242071602487;[CAV1, ATP1B1]
GO:1904886;beta-catenin destruction complex disassembly;5.0;1.0;0.7902410118609202;9.628524252492122;38.04764185170599;6.7325511899570465;0.0012734203321220245;0.6345439928109722;[FZD5, CAV1, PPP1CA]
GO:0001662;behavioral fear response;5.0;1.0;0.7902410118609202;9.628524252492122;37.889479621082295;6.375876246018314;0.0012681267845998157;0.6163036195908642;[DRD4]
GO:0048550;negative regulation of pinocytosis;8.0;0.9326813400603323;0.8413406700301662;9.56398573135455;174.57219107609745;8.16763571524637;0.005842774130545118;0.7926932703116032;[NR1H2, CAV1]
GO:0032417;positive regulation of sodium:proton antiporter activity;11.0;1.0;0.9324289523296623;9.628524252492122;842.887139998128;8.390779266560578;0.028210674026560526;0.8615337942327104;[ACTN4, DRD4]
GO:0001657;ureteric bud development;8.0;1.0;0.875;9.628524252492122;36.921511297847346;6.139487467954083;0.0012357297559360753;0.6889736746265369;[TGFB1, EPCAM, SDC1]
GO:0042053;regulation of dopamine metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.446202695698167;57.43424041378585;6.781341354126479;0.001922272339188874;0.6977174774718518;[NR4A2, ITGAM, TACR3, DRD4]
GO:0001937;negative regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.36028873802138;6.193554689224359;0.002923870244906099;0.6676580400938822;[MEF2C, CAV1, PRL]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, CXCL16, VPREB3, LGALS3, VPREB1, EDNRB, C3AR1, IL6R, SLC16A3, CD177, CXADR, ATP1B2, ATP1B1, PRTN3, S100A8, GYPA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, IGLV1-44, IGHA1, ELANE, LYN, CCR1, TGFB1, GPR15, CAV1, TNFRSF10B, AZU1, DEFA1, SELE, SDC1, IGKV3-20, IGHM, ITGAM, CXCL1, SLC7A11, CXCL2, TREM1, OLR1, FFAR2, CCR6, CCR2, MMP9, CEACAM1, SLC7A7, SLC7A8, CEACAM6, PECAM1, CXCR5, CXCR4, IGKC, CXCR1, EPCAM, CXCR2, CD58, JAM2, JAM3, CD2, NLRP12, TEK]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PYCARD, PPP2R1A, TNFSF12, CAV1, G0S2, INHBA, PPP1CA, MAL, LTBR, ATF3, ITM2C]
GO:0010524;positive regulation of calcium ion transport into cytosol;12.0;0.811012628672052;0.8536266269261705;9.4949928598676;446.85811756486936;5.825829909099042;0.01495593904869991;0.7460535250702665;[CD19, CAV1, F2R, P2RX5, CD4]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[NRP1, NRP2, HMGB2, AKT1, GHSR, EGR3, ARG1, TNFSF12, NR4A1, LRG1, TEK]
GO:0030512;negative regulation of transforming growth factor beta receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.537552474286395;374.7458266990886;5.54296712308321;0.012542405570270547;0.6584675964488075;[TGFB1, CAV1, DNM2]
GO:0019217;regulation of fatty acid metabolic process;6.0;0.6181399273706679;0.6321902762754785;8.375761283996754;59.641021377846656;5.407625775213448;0.001996131312082062;0.599666546214876;[PTGS2, CNR1, AKT1, GHSR, DGAT2, NR1H2, CAV1, CEACAM1]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[SLA2, FGF5, GRAP2, MAP2K2, BTC, MELK, BTK, EPHA3, BLK, CSF2RB, LYN, BMX, PTK2, HBEGF, WEE1, TEK]
GO:0032092;positive regulation of protein binding;5.0;0.7090535922965819;0.6447678080092112;8.529911963824013;32.707776742429765;5.311165509025885;0.0010946998524811438;0.5618542629869587;[NRP1, PLXND1, LRRK2, MEF2C, MMP9, LRP1, PLK2, CAV1, RAN]
GO:0015871;choline transport;7.0;1.0;0.8509193652572005;9.628524252492122;80.15881372336156;7.697632086000634;0.002682843357072172;0.7445766281117727;[SLC44A1]
GO:0030193;regulation of blood coagulation;7.0;0.6696747006330769;0.685756715573739;8.935377071932177;65.68414019264287;5.420364800990877;0.0021983890603594525;0.628117073252615;[CD36, LYN, CAV1, F2R, CEACAM1, CD9, TLR4]
GO:1901386;negative regulation of voltage-gated calcium channel activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;1444.7215118124473;6.832634648514029;0.048353528835415834;0.781850206004675;[GEM, DRD4]
GO:0061099;negative regulation of protein tyrosine kinase activity;11.0;0.8653626801206646;0.8651102923899945;9.55953138100517;2158.5537617243776;6.481236761676141;0.07224485183265184;0.7638797017301124;[CAV1]
GO:0006641;triglyceride metabolic process;7.0;0.8436909121759173;0.7727648213451592;9.318369324188282;85.59385656069774;5.500407508664414;0.0028647493496168257;0.6322104610454062;[SLC22A4, DGAT2, ACSL1, CAV1]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[SLA2, GRAP2, AKT1, MAP2K2, VRK1, MELK, BTK, SIK1, BLK, LYN, BMX, PTK2, LRRK2, MAP4K1, CAMK4, TEK]
GO:0045048;protein insertion into ER membrane;8.0;0.8259837884571596;0.7879918942285797;9.280217558223907;56.10872226547124;7.9853141584524145;0.0018779084396536687;0.7833693374183408;[TRAM2]
GO:0023014;signal transduction by protein phosphorylation;8.0;0.7248374789738407;0.7374187394869203;9.153100555777048;203.92357026499027;3.9689311377000256;0.006825138377471068;0.5779713229561524;[, FGF5, KCNH1, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, LYN, TGFB1, PTK2, LAT, LRRK2, SPTAN1, MAP4K1, DUSP6, HBEGF, TEK]
GO:0032091;negative regulation of protein binding;5.0;0.6997970393407541;0.6401395315312973;8.48339194818912;32.716075545242866;5.171903441692378;0.0010949776059428606;0.5547323943871747;[LRRK2, STMN1, AKT1, AES, SLPI, CAV1, PPP1CA]
GO:1904659;glucose transmembrane transport;9.0;0.8436909121759173;0.8180860812682478;9.36615998802463;37.512677707980714;6.343086423195323;0.0012555155636680114;0.7206263598461826;[SORT1, SLC5A4]
GO:0060326;cell chemotaxis;5.0;0.6393367784920305;0.6099094011069355;8.152617732682543;30.286927728949156;4.458953633836253;0.0010136762146226118;0.5182721080578558;[CSF3R, CXCL16, LGALS3, EDNRB, CCRL2, C3AR1, IL6R, CXADR, S100A8, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, CCR10, CCR1, EGR3, AZU1, DEFA1, NR4A1, NRP1, HMGB2, CXCL1, CXCL2, CCR9, FFAR2, CCR6, CCR2, RHOG, GAB1, HBEGF, CXCR5, CXCR4, CXCR1, CXCR2]
GO:0007207;phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;80.58987167142863;7.9853141584524145;0.00269727047866701;0.7833693374183408;[CHRM1]
GO:0043270;positive regulation of ion transport;6.0;0.5280135766324326;0.5871271009063608;7.175366301018702;46.28499923684045;4.288135901523783;0.00154911727066213;0.5424157820127834;[CHRM1, LGALS3, AKT1, F2R, ACTN4, ATP1B2, KMO, ATP1B1, KCNQ1, KCNE3, ABCB4, TNFRSF11A, CD19, DRD4, CCR1, WFS1, CYP4F2, CAV1, CTSS, DNM2, PTAFR, FLNA, P2RX5, CD4, P2RX1]
GO:0051289;protein homotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;5.433268205826786;0.002859955186148837;0.6287769539759931;[CDA, ACPP, FBP1, HM13, SAMHD1, CD79A]
GO:0046541;saliva secretion;6.0;1.0;0.8231203125901445;9.628524252492122;60.48885175748684;8.16763571524637;0.0020245074318908153;0.7408135829017477;[CHRM1]
GO:0031398;positive regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;528.4459358446122;5.113634533568402;0.01768660990225356;0.6767525197159333;[LRRK2, SKP2, NDFIP2, WFS1, CAV1]
GO:0055002;striated muscle cell development;5.0;0.7586651285174919;0.6695735761196662;8.935377071932177;32.84635378887841;5.382624473008031;0.001099337901514535;0.5655086777281872;[SLC8A1, CXADR, SDC1]
GO:0010976;positive regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;493.1928131726474;4.231896183200907;0.016506719612173492;0.6126599927924817;[SCARB2, CYFIP1, CPNE5, PLXND1, EPHA3, LYN, EZH2, NRP1, NLGN1, CNR1]
GO:0071455;cellular response to hyperoxia;6.0;1.0;0.8231203125901445;9.628524252492122;99.6623809530134;7.8311634786251565;0.0033356102001776892;0.7236063770733796;[CAV1, FOXO1]
GO:0031397;negative regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;529.4632463014641;5.572381008289503;0.01772065836772442;0.7002128357670632;[AKT1, FBXO5, CAV1]
GO:0051965;positive regulation of synapse assembly;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;224.643362448917;5.602686357784832;0.007518611175264769;0.6374410061458773;[NLGN1, AMIGO3]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, GRM5, EDNRB, CCRL2, CCR9, CCR6, CCR2, ATP1B1, LAT2, BTK, CXCR5, CXCR4, FPR2, CXCR1, CXCR2, CCR10, CCR1, AZU1, SELE, LAT]
GO:2001244;positive regulation of intrinsic apoptotic signaling pathway;9.0;0.7671156992804218;0.7797984748205;9.413412872875176;596.4251749563025;5.75172193694532;0.019961813857978603;0.6903839525180965;[NACC2, CAV1, ATF3, S100A8]
GO:0034141;positive regulation of toll-like receptor 3 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;505.2767808384828;7.8311634786251565;0.01691115913508416;0.7967266896635242;[CAV1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[EDNRB, GPR171, C3AR1, AKT1, PROK2, TAS2R10, TRHR, ADCY9, FPR1, FPR3, FPR2, CCR10, CCR1, ABCA1, GPR15, FZD5, AZU1, MARCO, PNOC, GPR18, GPR19, GPR25, CD3E, CCR9, FFAR2, CCR6, CCR2, RHOG, GPBAR1, TACR3, AGTRAP, SORCS3, PTAFR, CXCR5, CXCR4, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, GABRE, GPR157, P2RY13, GABBR1, SORT1, P2RY14, GPR6, RAMP1, LGR4, CHRM1, CELSR1, CXCL16, RGS1, CCRL2, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, SUCNR1, CALCRL, C5AR1, GPR84, HRH4, DRD4, HTR1E, CAV1, GNB2, TAS2R7, OR1G1, CXCL1, CXCL2, GRM5, PTGIR, GLP2R, LRP1, P2RY6, CNR1, P2RY2, S1PR3, TSHR, OR11A1]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[LRRK2, RUVBL1, JUP, CAV1, SULF2, LGR4]
GO:0043552;positive regulation of phosphatidylinositol 3-kinase activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;732.6859750532908;6.375876246018314;0.024522340210466318;0.7584915600596062;[LYN, TGFB1, FPR2, PTK2, TEK]
GO:0045454;cell redox homeostasis;5.0;1.0;0.7902410118609202;9.628524252492122;31.944097044200298;5.572381008289503;0.0010691401802485107;0.5752128357670632;[TXNDC15, SLC11A1]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[SCARB2, TFRC, HP, CXCL16, AP2M1, CALCRL, FPR2, IGLV1-44, IGHA1, MSR1, CD163, CAV1, MARCO, IGKV3-20, LRP12, ASGR1, ASGR2, CD36, DNM2, CEACAM1, COLEC12, LRP1, IGKC, CXCR1, CXCR2, FCGR1B, LILRB1, CD9, FCGR2B, RAMP1]
GO:0006656;phosphatidylcholine biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.398000593880289;749.286726231254;6.343086423195323;0.025077952412686653;0.6993857346658935;[SLC44A1]
GO:0043434;response to peptide hormone;6.0;0.6696747006330769;0.657957662906683;8.712233520617966;71.32532737153224;4.149452513989832;0.0023871945184980284;0.5353235071248601;[CYFIP1, CTGF, EDNRB, AKT1, GHSR, LHCGR, POR, ADCY9, ABCB4, FOXO1, PRKAR2B, LYN, EGR1, EGR2, TGFB1, CAV1, CDC6, NR4A2, NR4A1, HHEX, ARG1, GLP2R, CEACAM1, TLR2, RETN, PTGS2, GNAI1, SORT1, TSHR, TEK]
GO:1903609;negative regulation of inward rectifier potassium channel activity;12.0;1.0;0.9481203125901445;9.628524252492122;1503.7936590381803;9.777073627680469;0.050330620441580154;0.9481203125901445;[CAV1]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[MEF2C, TGFB1, ARG1, CAV1, NOX4]
GO:0030857;negative regulation of epithelial cell differentiation;6.0;0.6634067003016617;0.6548236627409754;8.638125548464245;143.89713366415532;6.139487467954083;0.004816107564726769;0.6370939872166814;[JAG1, CAV1, S1PR3, EZH2]
GO:0050482;arachidonic acid secretion;12.0;1.0;0.9481203125901445;9.628524252492122;224.85573033724626;6.599019797332524;0.007525718937368459;0.7855944919115336;[ACE, DRD4]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, IQGAP3, JAG1, JUP, AZU1, MMP12, PTAFR, ATAD2, LGR4, CTGF, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, CD28, BRCA2, CD3E, CD36, CCNE1, CAV1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, CD4, RAN, EHF, MYB, NUP85, NFE2, FZD5, PAWR, PAX5, ENG, EPCAM, GSN, NR1H2, GTF2H1, PLXND1, CDH3, CDH1, MAP2K2, F2R, ADAM2, MAFF, RFC1, CEBPE, KLF5, CHEK1, SLC11A1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, CAMK4, ARID4A, HGS, STAP1, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0072012;glomerulus vasculature development;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;29.790612467550705;8.16763571524637;9.970649894783417E-4;0.7686126355688037;[TEK]
GO:0034776;response to histamine;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;62.89298739988266;7.379178354882098;0.002104971688260197;0.6676125360964777;[DRD4]
GO:2000286;receptor internalization involved in canonical Wnt signaling pathway;8.0;1.0;0.875;9.628524252492122;66.79409571189065;8.67846133901236;0.0022355382726935618;0.8188169164668168;[CAV1]
GO:0031664;regulation of lipopolysaccharide-mediated signaling pathway;6.0;0.8653626801206646;0.7558016526504768;9.461470167828956;82.5062356598439;6.599019797332524;0.002761409456743651;0.6605944919115335;[SCARB2, CD180, LY96, LTF]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[SCARB2, TFRC, ANPEP, CLEC5A, ITGB6, CR2, CR1, CXADR, GYPA, GPR15]
GO:0007271;synaptic transmission, cholinergic;8.0;1.0;0.875;9.628524252492122;25.73829654599903;6.409777797693995;8.61437622431563E-4;0.7027963346592216;[CHRNB4, CHRM1]
GO:0007274;neuromuscular synaptic transmission;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;25.73829654599903;6.250713103064308;8.61437622431563E-4;0.6946617587785947;[CHRNB4, EGR3, CHRM1]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[CAV1, PTAFR, F2R, PTGS2, AKT1]
GO:0006464;cellular protein modification process;6.0;0.33881133730344803;0.4925259812418685;5.842712558201993;147.0276183392271;1.7630686329010112;0.004920882069548126;0.41328372446777834;[, SLA2, AKT1, DUSP2, DUSP1, DUSP6, PKN1, KCNH1, BLK, PKMYT1, BMX, BTC, BTK, SDC2, EGR2, PTK2, MUC15, SPTAN1, PCNA, UBE2M, TEK, ST3GAL6, IGHA1, BARD1, PLK2, ASGR1, ASGR2, CIT, NUCB1, FGF5, MAP2K2, VRK1, NRBP1, CCDC22, LAT, NLRC4, PPIL4, PPP2R1A, ESCO2, POR, SIK1, TLR7, TLR4, TLR2, QPCT, NLRP3, CBX4, HIST1H2BK, BUB1, WEE1, EHMT2, KRTCAP2, MEF2C, PADI2, IQGAP3, LYN, ABCA1, EZH2, F5, F13A1, RUVBL1, S100A8, FOXO1, PTPRE, ST6GALNAC2, LRRK2, CCNH, EPHA3, PTPRR, FKBP14, PTPRK, BRCA2, CTSG, PPP1CA, GXYLT2, CCNE1, KLHL14, RASGRP4, GALNT6, CDK14, HBEGF, FAM105A, GTF2H1, CHRM1, ABHD12, GRAP2, MACROD2, STK32B, MELK, NACC2, IGFBP7, WFS1, MARCH3, MARCH1, RNF24, CHEK1, SKP2, BCL11A, MAP4K1, B3GNT5, SGK1, CAMK4, ARID4A, CSF2RB, TGFB1]
GO:0006465;signal peptide processing;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;245.95175762031633;7.004484905440688;0.008231783985340883;0.7091290490632969;[HM13]
GO:0051591;response to cAMP;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;79.54904468548885;5.192106149009898;0.0026624349361310785;0.5886448625081389;[PTAFR, AQP9, SLC8A1, DUSP1, KCNQ1, NOX4, SDC1, TEK, SLC26A3]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[GJC1, HHEX, TGFB1, CAV1, PTK2, ENG]
GO:0006622;protein targeting to lysosome;11.0;0.9326813400603323;0.8987696223598284;9.592156608321247;250.3799473132135;6.781341354126479;0.008379991509250163;0.7792270645443136;[SCARB2, HGS, LAMP2]
GO:1901844;regulation of cell communication by electrical coupling involved in cardiac conduction;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;47.34252427509125;7.57984905034425;0.0015845116819816402;0.7626338329336335;[CAV1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, EDNRB, PCBP3, EGR1, BCL11A, XPO1, CD36, CCNE1, TGFB1, CBX4, CAV1, NR4A2, MXD1, FBP1, MEIS2]
GO:0001960;negative regulation of cytokine-mediated signaling pathway;7.0;0.7140352122741334;0.7079369713942671;8.965230035081857;244.80256319284138;5.8067817141283475;0.008193321482061134;0.6478784521606894;[STAP1, ARG1, NR1H2, IL1R2, CAV1, MMP12, PADI2]
GO:0032507;maintenance of protein location in cell;5.0;0.6763753087927167;0.6284286662572787;8.412128928167629;43.86076268124676;5.4730085344763;0.0014679802548176633;0.5701309228349632;[AKT1, TLN1, BARD1, GSN, JUP, CAV1, CD4]
GO:0051586;positive regulation of dopamine uptake involved in synaptic transmission;9.0;1.0;0.896240625180289;9.628524252492122;542.8436285639937;8.67846133901236;0.018168487720489054;0.8400575416471059;[DRD4]
GO:0009968;negative regulation of signal transduction;6.0;0.43649654099988644;0.5413685830900877;6.680044863788677;140.65047919891595;2.686163805600486;0.0047074449615745265;0.460490854527945;[, PID1, SLA2, STMN1, AKT1, UBASH3A, PADI2, ATF3, FIGNL1, LYN, EZH2, LRRC4, DUSP2, DUSP1, ARG1, FCRL3, PAWR, DUSP6, AES, MMP12, PTGS2, NR1H2, SULF2, LGR4, PYCARD, TLE4, LY96, FOXO1, WFS1, TNFRSF10B, PTPRE, BCL6, CCDC22, LRRK2, HHEX, LRP1, LGALS3, PPP2R1A, IL1R2, RUNX2, SIK1, EPHA3, APCDD1, EGR1, VNN1, NRP1, PTPRR, CD3E, CEACAM1, BANK1, TLR4, GNAI2, NLRP12, GRINA, RGS1, TSC2, HGS, STAP1, NLRP3, TGFB1, CAV1, NR4A2, HMGB2, NUP62, PTGIR, ARAP3, MMP9, DNM2, FBP1, LTF, CLEC12B, TEK]
GO:0001964;startle response;5.0;1.0;0.7902410118609202;9.628524252492122;22.2265316404705;7.212124270218933;7.439020114267487E-4;0.659069382437994;[KCNH1]
GO:0034765;regulation of ion transmembrane transport;6.0;0.45556283921517005;0.5509017321977295;6.676594601596523;33.03735142972539;3.697140432584879;0.0011057304206669666;0.512192246247148;[, KCNG2, SLC8A1, AKT1, SCN1A, KCNH1, MEF2C, F2R, CACNA2D3, ACTN4, ATP1B2, ATP1B1, GEM, KCNQ1, KCNE3, KCNE4, HVCN1, CORO1A, CD19, DRD4, LYN, TGFB1, CAV1, FXYD6, KCNK5, CTSS, GRM5, MMP9, DNM2, TMEM37, NLGN1, PTAFR, FLNA, KCNJ15, KCNJ16, TSPAN13]
GO:0010952;positive regulation of peptidase activity;9.0;0.7140352122741334;0.7532582313173557;9.377209824211215;435.08389316762396;4.595290077388384;0.014561866354238107;0.6312439734407735;[CTGF, PYCARD, F2R, S100A8, NLRP3, LYN, CAV1, TNFRSF10B, CR1, NLRC4, GSN, NLRP12, P2RX1]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[LRRK2, CDH3, FZD5, NR4A2, SDC1, LGR4]
GO:0098911;regulation of ventricular cardiac muscle cell action potential;10.0;0.7866048967936545;0.8085434602577476;9.537552474286395;102.35229487303722;7.138016298065211;0.0034256391983155283;0.7802794972956796;[JUP, KCNE3, CAV1]
GO:0035176;social behavior;3.0;1.0;0.6981203125901445;9.628524252492122;22.58175877758554;5.8067817141283475;7.557911440223213E-4;0.49507939949363344;[NLGN4Y, NRXN3, DRD4]
GO:1900085;negative regulation of peptidyl-tyrosine autophosphorylation;11.0;1.0;0.9324289523296623;9.628524252492122;1790.2607340613608;9.777073627680469;0.05991841563897651;0.9324289523296623;[CAV1]
GO:0050709;negative regulation of protein secretion;8.0;0.6493065804076676;0.6996532902038338;8.749274792298316;381.9718045319581;5.058574756385375;0.01278425254537885;0.6336957482893315;[IFNA2, GHSR, IL1R2, F2R, BANK1, TLR8, NLRP3, DRD4, LILRB1, NLRP12, FCGR2B, LGR4]
GO:1903598;positive regulation of gap junction assembly;7.0;1.0;0.8509193652572005;9.628524252492122;133.85571530024345;8.67846133901236;0.004480030328776454;0.7947362817240173;[CAV1]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, SLA2, C3AR1, AKT1, MEF2C, HHLA2, FPR1, FPR3, FPR2, PDGFC, LYN, ABCA1, JAG1, HLA-DRB4, VANGL1, SIGLEC9, LRRC4, PTAFR, PTGS2, FLNA, P2RY13, P2RY14, LGR4, NCF4, F13A1, CTGF, AP2M1, LAG3, IFNA14, IFNA16, IFNA10, BLK, CD274, TACSTD2, LY96, TNFRSF11A, CORO1A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, BMX, LCN2, HLA-DRA, CIITA, ITGAM, ITGB4, LRRK2, HHEX, FCGR3A, ITGB6, TNFRSF1B, TSPAN33, FCGR1B, TSPAN13, FCGR2A, FCGR2B, ICAM2, BTC, BTK, EPHA3, SDC2, TGFA, CD19, TSPAN5, TSPAN2, CCR1, EGR1, TNFSF12, PTK2, CD28, SDC1, CD24, IGHM, NRP1, PTPRR, NRP2, TNFRSF13B, CD3G, PTPRK, CD3E, CCR9, FCER1A, CD37, CCR6, MUC15, CD36, CCR2, GAB1, LAT2, IGHD, GNAI2, IGKC, SORT1, CELSR1, CCRL2, IL6R, GEM, OSCAR, CCNE1, PSEN2, RASGRP4, CRIM1, INHBA, GH1, IGKV3-20, SIRPB1, GRM5, NUP62, MMP9, SAMHD1, CD2, CD4, CD7, CD9, TEK, CDA, CYFIP1, STMN1, GPR171, IGHA1, HLA-DQA1, FZD5, CDK14, DENND1B, CDKN1A, ASGR2, NFAM1, AES, FCER2, HBEGF, ENG, HLA-DQB1, ALOX5, GPR157, G0S2, SULF2, ZYX, CSF3R, PLXND1, FGF5, PYCARD, CDH5, IGHG1, CDH3, FCGRT, GRAP2, IL13RA2, TLE4, CLEC4D, ADAM9, CD151, CALCRL, IGLV1-44, BCL6, LAT, CR2, CR1, P2RY6, P2RY2, P2RX5, P2RX1, EDNRB, ICOSLG, ACSL1, IL1R1, IL1R2, RUNX2, TLN1, PFN1, APCDD1, CD79B, CD79A, CCR10, MARCO, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, GP1BB, GPBAR1, PDCD1LG2, IL17RB, CEACAM1, RHOU, TLR4, TLR2, CXCR5, CXCR4, CXCR1, CXCR2, LILRB1, LILRB2, LILRB3, KRT19, IL18RAP, TSC2, KIF16B, PRTN3, C5AR1, CSF2RB, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, BLNK, GLP2R, CLEC12B, REPS2, S1PR3, TRAT1, TSHR, LTBR]
GO:0007205;protein kinase C-activating G-protein coupled receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;6.444869117505266;9.028936615729279E-4;0.6527112189764278;[CHRM1, LRP1, F2R, AZU1, DGKZ]
GO:0006631;fatty acid metabolic process;7.0;0.5408746917014966;0.6213567111079488;7.849668188099975;91.0232021896581;4.037280715501235;0.0030464646617242943;0.5573860888006872;[, SCARB2, ACSL1, POR, SLC27A2, MGST1, PRKAR2B, CYP4F2, CYP4F3, TBXAS1, TECR, ELOVL4, PTGS2, ALOX5, SCD]
GO:0048627;myoblast development;4.0;1.0;0.75;9.628524252492122;32.15320660831846;9.083926447120524;0.001076138889173156;0.714552420951524;[SDC1]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CD24, GPR18, CCR9, CCR6, CD36, CCR2, CD52, PTGIR, CXCR5, CXCR4, CXCR1, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, ATP1B1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, ELANE, CCR10, DRD4, CCR1, TGFB1, WFS1, CAV1, CD24, GPR18, ATP2A3, GRM5, CCR9, CCR6, CD36, CCR2, CD52, PTGIR, SLC24A1, SLC24A4, CXCR5, CXCR4, CXCR1, SV2A, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, GRINA]
GO:0090090;negative regulation of canonical Wnt signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;236.99226377157444;4.932886541221878;0.00793191778924446;0.6272680471207706;[TLE4, AES, FOXO1, EGR1, CAV1]
GO:0009617;response to bacterium;5.0;0.7508913569872202;0.6656866903545304;8.935377071932177;27.267803904038782;3.9481280100702625;9.126288572378991E-4;0.49214846190264216;[, HP, PYCARD, IGHG1, IL6R, SLC11A1, RNASE6, RNASE3, CHIT1, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, NLRP3, IGHA1, ELANE, DEFA4, CAV1, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, HMGB2, CTSG, CD36, CAMP, ANXA3, TLR1, IGHD, BPI, TLR5, TLR4, LTF, TLR2, CEBPE, HIST1H2BK, PTAFR, NLRC4, IGKC, CD4, FCGR2B]
GO:0001975;response to amphetamine;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;70.50276562849314;6.558197802812269;0.0023596641172160164;0.6585068532133508;[NR4A2, DRD4]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CXCR5, CXCR4, CXCL1, CXCL2, CXCR1, CXCR2, CCRL2, CCR9, CCR6, CCR10, CCR2, CCR1]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, PYCARD, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, CHI3L1, GNAI2, GPNMB, CD4, TEK]
GO:1903071;positive regulation of ER-associated ubiquitin-dependent protein catabolic process;12.0;1.0;0.9481203125901445;9.628524252492122;6504.6704340352835;7.8311634786251565;0.2177054656038327;0.8486063770733797;[CAV1]
